Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease

Kyoung-Woon Kim; Su-Jin Moon; Min-Jung Park; Bo-Mi Kim; Eun-Kyung Kim; Sung-Hee Lee; Eun-Jung Lee; Byung-Ha Chung; Chul-Woo Yang; Mi-La Cho
October 2015
Stem Cell Research & Therapy;10/23/2015, Vol. 6, p1
Academic Journal
Introduction: Mesenchymal stem cells (MSCs) can protect bone marrow transplantation (BMT) recipients from the lethal acute graft-versus-host disease (aGVHD) development. However, the mechanisms underlying the anti-inflammatory properties of MSCs in aGVHD remain to be elucidated. The immunoregulatory properties of MSCs are mediated by their production of anti-inflammatory molecules, including IL-10 and TGF-β. On the other hand, MSCs can also produce proinflammatory cytokines during their normal growth, such as IL-1β and IL-6. These opposite actions may limit their therapeutic application in aGVHD. Therefore, optimization of the functional properties of MSCs can increase their benefits. Methods: The expressions of mRNA and protein were analyzed by real-time PCR and western blotting, respectively. Expression of MSC markers was assessed by flow cytometry. An animal model of aGVHD was established by transplanting C57BL/6 donor bone marrow cells and spleen cells into lethally irradiated BALB/c recipient mice. The recipient mice were divided into the control group and the therapy [adipose tissue-derived human MSCs (Ad-hMSCs) or rapamycin-treated Ad-hMSCs] groups. The survival, body weight and clinical score of aGVHD in transplanted mice were monitored. Results: Rapamycin pre-treatment of Ad-hMSCs increased mRNA synthesis of IL-10, indoleamine 2,3-dioxygenase, and TGF-β compared with untreated Ad-hMSCs. Rapamycin-treated Ad-hMSCs suppressed clonal expansion of interleukin-17-producing CD4+ T (Th17) cells more effectively than untreated cells. mRNA expression of autophagy markers such as ATG5, LC3A and LC3B was significantly increased in the rapamycin-treated Ad-hMSCs compared with untreated Ad-hMSCs. Transmission electron microscopy revealed that Ad-hMSCs exposure to rapamycin resulted in the appearance of autophagic vacuoles. Interestingly, in vitro migration efficiency of rapamycin-treated Ad-hMSCs toward the CD4+ T cells was increased significantly compared with the untreated cells. And, these effects were associated with autophagy induction capacity of rapamycin. In vivo, the inhibiting properties of MSCs on the clinical severities of aGVHD were greater in the mice receiving rapamycin-treated Ad-hMSCs compared with untreated Ad-hMSCs. The beneficial effects of rapamycin treatment in Ad-hMSCs shown in vivo were associated with a reduction of Th17 cells and an increase in regulatory T cells. Conclusions: Rapamycin can optimize the immunomodulatory potential of Ad-hMSCs, suggesting a promising strategy of MSC use in aGVHD treatment.


Related Articles

  • MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Kordelas, L; Rebmann, V; Ludwig, A-K; Radtke, S; Ruesing, J; Doeppner, T R; Epple, M; Horn, P A; Beelen, D W; Giebel, B // Leukemia (08876924);Apr2014, Vol. 28 Issue 4, p970 

    A letter to the editor is presented concerning a study which examines mesenchymal stem cells (MSCs)-derived exosomes as treatment for refractory graft-versus-host disease (GvHD).

  • Presence and function of microRNA-92a in chondrogenic ATDC5 and adipose-derived mesenchymal stem cells. CHANGHE HOU; ZIJI ZHANG; ZHIQI ZHANG; PEIHUI WU; XIAOYI ZHAO; MING FU; PUYI SHENG; YAN KANG; WEIMING LIAO // Molecular Medicine Reports;2015, Vol. 12 Issue 4, p4877 

    The aim of the present study was to investigate the presence and biological function of microRNA-92a (miR-92a) in chondrogenesis and cartilage degeneration. Human adipose-derived mesenchymal stem cells (hADSCs) in micromass and chondrocyte-like ATDC5 cells were induced to chondrogenesis, and...

  • Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bernardo, M E; Pagliara, D; Locatelli, F // Bone Marrow Transplantation;Feb2012, Vol. 47 Issue 2, p164 

    Because of their immunomodulatory and engraftment-promoting properties, mesenchymal stromal cells (MSCs) have been tested in the clinical setting both to facilitate haematopoietic recovery and to treat steroid-resistant acute GVHD. More recently, experimental findings and clinical trials have...

  • Oral Session 32 (Plaza Ballroom): Therapy-Stem Cells.  // Journal of Extracellular Vesicles;2013, Vol. 2, p137 

    The article presents abstracts on topics related to therapy/stem cells which include biochemical potential of mesenchymal stem cell (MSC) exosomes, effectiveness of membrane TRAIL-armed exosomes as an anti-tumor therapy, and role of mesenchymal stem-cell derived exosomes on the treatment of...

  • Mesenchymal stromal cells as treatment for chronic GVHD. Ringden, O.; Keating, A. // Bone Marrow Transplantation;Feb2011, Vol. 46 Issue 2, p163 

    The authors reflect on the use of mesenchymal stromal cells (MSCs) as treatment for acute graft versus host disease (GVHD). The authors discuss the study of J. Y. Weng and colleagues on medical outcomes of 19 patients who were treated with MSCs for refractory chronic GVHD. They mention that one...

  • Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Dander, E; Lucchini, G; Vinci, P; Introna, M; Masciocchi, F; Perseghin, P; Balduzzi, A; Bonanomi, S; Longoni, D; Gaipa, G; Belotti, D; Parma, M; Algarotti, A; Capelli, C; Golay, J; Rovelli, A; Rambaldi, A; Biondi, A; Biagi, E; D'Amico, G // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1681 

    The article presents a study which examines the biological effect of mesenchymal stromal cells (MSCs) on the treatment of graft-versus-host disease (GvHD). The study was participated by 10 patients with post-transplant GvHD who were managed with multiple infusions of third-party bone...

  • Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. te Boome, L C J; Mansilla, C; van der Wagen, L E; Lindemans, C A; Petersen, E J; Spierings, E; Thus, K A; Westinga, K; Plantinga, M; Bierings, M; Broers, A E C; Cuijpers, M L H; van Imhoff, G W; Janssen, J J; Huisman, C; Zeerleder, S; Huls, G; Boelens, J J; Wulffraat, N M; Slaper-Cortenbach, I C M // Leukemia (08876924);Sep2015, Vol. 29 Issue 9, p1839 

    We performed a prospective phase II study to evaluate clinical safety and outcome in 48 patients with steroid-refractory grade II-IV acute graft-versus-host disease (aGVHD) treated with mesenchymal stromal cells (MSCs). Clinical outcomes were correlated to comprehensive analyses of soluble and...

  • Advances in Adipose-Derived Stem Cells Isolation, Characterization, and Application in Regenerative Tissue Engineering. Wankhade, Umesh D.; Shen, Michael; Kolhe, Ravindra; Fulzele, Sadanand // Stem Cells International;2/11/2016, p1 

    Obesity is a complex, multifactorial disease that has been extensively researched in recent times. Obesity is characterized by excess deposition of adipose tissue in response to surplus energy. Despite the negative connotations of adipose tissue (AT), it serves as a critical endocrine organ....

  • Preparation and characteristics of growth and marker properties of urinary bladder mesenchymal stem cells. Zhidkova, O.; Petrov, N.; Popov, B. // Journal of Evolutionary Biochemistry & Physiology;Jan2013, Vol. 49 Issue 1, p105 

    Mesenchymal stem cells (MSC) are able to transdifferentiate into cells with different functional phenotypes and considered as a promising resource for regenerative therapy. MSC derived from different tissues vary in their differentiation potential and in some cases express tissue specific...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics